Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alok Gopal

Interventional Pain Medicine Winchester, VA Medical Doctor

NPI 1174588107 CMS profile 8043

190 Campus Blvd, Ste 420, Winchester, VA 22601

Open in the dashboard

General payments

$15,575

601 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alok Gopal of Winchester, VA is reported in the CMS Open Payments database as having received $15,575 across 601 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,092 86
2024 General $1,617 72
2023 General $1,785 78
2022 General $3,753 106
2021 General $1,762 93
2020 General $1,105 64
2019 General $2,462 102

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alok Gopal
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Alok Gopal were reported at $3,092. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Alok Gopal Interventional Pain Medicine median Middle half National median
2019 $2,462 $684 $216–$2,079 $163
2020 $1,105 $382 $122–$1,109 $114
2021 $1,762 $552 $167–$1,554 $132
2022 $3,753 $605 $187–$1,924 $149
2023 $1,785 $671 $195–$1,915 $160
2024 $1,617 $684 $206–$1,837 $164
2025 $3,092 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $3,218 93 payments
  2. Abbott Laboratories $2,472 119 payments
  3. Boston Scientific Corporation $1,163 41 payments
  4. Collegium Pharmaceutical, Inc. $1,058 73 payments
  5. Nevro Corp. $803 24 payments
  6. Medtronic USA, Inc. $510 21 payments
  7. BIOTRONIK NRO, Inc. $482 8 payments
  8. TerSera Therapeutics LLC $453 21 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $443 27 payments
  10. Biodelivery Sciences International, Inc. $418 26 payments
  11. Other $4,554 148 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,457 588 payments
  2. Travel and Lodging $1,049 10 payments
  3. Education $69 3 payments
Products named General payments · program years 2019–2025
  1. SYNCHROMEDII $2,357 36 payments
  2. XTAMPZA $928 53 payments
  3. PROCLAIM $550 25 payments
  4. GENERAL PAIN MANAGEMENT $513 16 payments
  5. INTELLIS $486 19 payments
  6. Prospera $482 8 payments
  7. Qutenza $471 14 payments
  8. Senza $467 13 payments
  9. Proclaim Family of SCS IPGs $429 13 payments
  10. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $382 2 payments
  11. Other $9,757 460 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,615

Median for Anesthesiology: 322

Drug cost

$67,391

Median for Anesthesiology: $8,738

Branded share of claims

35.9%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 41 $24,527
Pregabalin Generic 290 $7,499
Buprenorphine Generic 43 $5,924
Oxycontin Oxycodone Hcl Brand 11 $5,859
Fentanyl Generic 59 $4,455
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 236 $4,152
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 174 $3,170
Morphine Sulfate Er Morphine Sulfate Brand 89 $2,361
Lidocaine Generic 19 $2,211
Gabapentin Generic 122 $1,684

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$371,458

Of which drugs: $22,105

Medicare patients

439

Average age 74

Services billed

6,587

277 women, 162 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 39%
Depression 33%
Chronic kidney disease 31%
Ischemic heart disease 29%
COPD 23%
Atrial fibrillation 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 11 640 $8,860
Injection, methylprednisolone acetate, 1 mg J1010 Office 13 1,280 $65
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 50 343 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTAMPZA
  • Collegium Pharmaceutical, Inc. $204
$204 41 —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $57
$57 — —
Prialt
  • TerSera Therapeutics LLC $34
$34 — —
Crysvita
  • Kyowa Kirin, Inc. $20
$20 — —
Tirosint
  • IBSA Pharma Inc. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

601 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record